UnitedHealth Group (UNH) Scheduled to Post Quarterly Earnings on Tuesday

UnitedHealth Group (NYSE:UNH) is scheduled to post its quarterly earnings results before the market opens on Tuesday, January 16th. Analysts expect UnitedHealth Group to post earnings of $2.50 per share for the quarter. UnitedHealth Group has set its FY17 guidance at $10.00 EPS.

UnitedHealth Group (NYSE:UNH) last released its quarterly earnings results on Tuesday, October 17th. The healthcare conglomerate reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.09. UnitedHealth Group had a net margin of 4.50% and a return on equity of 21.52%. The company had revenue of $50.32 billion during the quarter, compared to the consensus estimate of $50.38 billion. During the same period in the previous year, the business earned $2.17 earnings per share. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. On average, analysts expect UnitedHealth Group to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Shares of UnitedHealth Group (UNH) opened at $228.64 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.70 and a quick ratio of 0.70. UnitedHealth Group has a 1 year low of $156.09 and a 1 year high of $231.77. The firm has a market cap of $221,060.00, a P/E ratio of 25.98, a PEG ratio of 1.53 and a beta of 0.66.

In other news, Director Gail R. Wilensky sold 5,600 shares of the company’s stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $223.31, for a total transaction of $1,250,536.00. Following the completion of the transaction, the director now directly owns 61,137 shares in the company, valued at $13,652,503.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Thomas E. Roos sold 975 shares of the company’s stock in a transaction on Thursday, October 19th. The stock was sold at an average price of $205.47, for a total transaction of $200,333.25. Following the transaction, the insider now owns 24,630 shares of the company’s stock, valued at $5,060,726.10. The disclosure for this sale can be found here. Insiders have sold 34,630 shares of company stock valued at $7,669,416 over the last quarter. Company insiders own 0.89% of the company’s stock.

Large investors have recently made changes to their positions in the company. Intellectus Partners LLC increased its holdings in shares of UnitedHealth Group by 18.2% during the second quarter. Intellectus Partners LLC now owns 818 shares of the healthcare conglomerate’s stock worth $152,000 after buying an additional 126 shares in the last quarter. Bank of Nova Scotia grew its stake in shares of UnitedHealth Group by 7.8% in the second quarter. Bank of Nova Scotia now owns 447,793 shares of the healthcare conglomerate’s stock worth $83,030,000 after purchasing an additional 32,405 shares during the last quarter. M&R Capital Management Inc. grew its stake in shares of UnitedHealth Group by 14.8% in the second quarter. M&R Capital Management Inc. now owns 1,550 shares of the healthcare conglomerate’s stock worth $299,000 after purchasing an additional 200 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in shares of UnitedHealth Group by 6.5% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 367,044 shares of the healthcare conglomerate’s stock worth $68,070,000 after purchasing an additional 22,428 shares during the last quarter. Finally, Assetmark Inc. grew its stake in shares of UnitedHealth Group by 4.7% in the second quarter. Assetmark Inc. now owns 118,027 shares of the healthcare conglomerate’s stock worth $21,885,000 after purchasing an additional 5,317 shares during the last quarter. Institutional investors own 86.01% of the company’s stock.

Several research analysts have commented on the stock. Evercore ISI restated an “outperform” rating and set a $255.00 price objective (up from $235.00) on shares of UnitedHealth Group in a research report on Friday. Wells Fargo & Co restated an “outperform” rating and set a $245.00 price objective (up from $230.00) on shares of UnitedHealth Group in a research report on Wednesday, November 29th. Leerink Swann restated an “outperform” rating on shares of UnitedHealth Group in a research report on Friday, December 1st. Citigroup boosted their price objective on shares of UnitedHealth Group from $213.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, October 18th. Finally, BMO Capital Markets assumed coverage on shares of UnitedHealth Group in a research report on Monday, October 16th. They set an “outperform” rating and a $250.00 price objective for the company. Three research analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $229.54.

ILLEGAL ACTIVITY WARNING: “UnitedHealth Group (UNH) Scheduled to Post Quarterly Earnings on Tuesday” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thestockobserver.com/2018/01/14/unitedhealth-group-unh-scheduled-to-post-quarterly-earnings-on-tuesday.html.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Earnings History for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply